Oryzon Genomics has established primary and key secondary endpoints for its Phase III clinical trial of vafidemstat for Borderline Personality Disorder (BPD). This was achieved with input from a newly formed Clinical Advisory Board comprised of leading psychiatric experts. The company anticipates submitting the Phase III protocol to the FDA in the first half of 2025.
This development is crucial because it signifies a concrete step towards addressing the unmet need for effective BPD treatments, especially for managing agitation and aggression. The involvement of a high-profile advisory board lends credibility to the trial design and increases confidence in the potential of vafidemstat to meaningfully impact patient outcomes. A clearly defined and FDA-aligned endpoint strategy enhances the likelihood of regulatory success, paving the way for a potential new therapy in a challenging therapeutic area.
The Phase III trial design builds upon positive feedback from the FDA regarding Oryzon’s Phase IIb PORTICO trial. The chosen endpoints, focused on agitation and aggression, utilize established assessment scales and directly address key symptoms that significantly impair the lives of individuals with BPD. This focus reflects a growing understanding of the importance of targeting these specific symptoms for improved patient management and quality of life.
This progress positions Oryzon to potentially initiate the Phase III trial soon after regulatory submission, pending funding acquisition. A successful Phase III trial could lead to the first approved treatment specifically targeting agitation and aggression in BPD, offering a much-needed option for patients and potentially reshaping the treatment landscape for this complex disorder. Furthermore, the research with vafidemstat in BPD could also inform the development of the drug for other conditions, including schizophrenia and various neurodevelopmental disorders, where it is currently being studied.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
